Thyroid Eye Disease clinical trials at University of California Health

6 in progress, 2 open to eligible people

Showing trials for

  • Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease

    open to eligible people ages 18 years and up

    This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with placebo PH20 SC. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive efgartigimod PH20 SC or placebo PH20 SC, respectively during the double-blinded treatment period (DBTP). At the end of the DBTP, participants may enter a follow-up observational period while off study drug. Some participants may also enter the open-label treatment period with efgartigimod PH20 SC. The study duration varies from approximately 60 to 110 weeks. An alternative list of clinical sites open for recruitment could be found in the other UplighTED study record (https://www.clinicaltrials.gov/study/NCT06307626)

    at UC Irvine

  • TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease

    open to eligible people ages 18-80

    Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.

    at UC Davis

  • Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

    Sorry, in progress, not accepting new patients

    The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).

    at UCLA UCSD

  • Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease

    Sorry, in progress, not accepting new patients

    The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).

    at UCSD

  • Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

    Sorry, in progress, not accepting new patients

    The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.

    at UCSD

  • Batoclimab in Participants With Active Thyroid Eye Disease

    Sorry, in progress, not accepting new patients

    To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.

    at UCSF

Last updated: